DSGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Design Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$10.64+0.33 (+3.20%)
Close on Oct 19, 2026
- Market cap
- $665.06M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$4.90 (+85.37%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Design Therapeutics, Inc. reported revenue of $0 for the twelve months to Jun 30, 2026. Free cash flow was -$55.14M.
Revenue
$0
TTM Q2 2026
Operating income
-$79.36M
TTM Q2 2026
Free cash flow
-$55.14M
TTM Q2 2026
EPS, diluted
-$1.18
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $665.06M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 3.29
- Dividend yield
- –
- Free cash flow yield
- -8.29%
Fundamentals
- Revenue
- $0
- Net income
- -$70.80M
- EPS, diluted
- -$1.18
- Free cash flow
- -$55.14M
- Book value per share
- $3.23
- Diluted shares
- 63M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
$0
Operating income
-$79.36M
Net income
-$70.80M
EPS, diluted
-$1.18
Free cash flow
-$55.14M
Reported periodTrailing twelve months